<bill session="116" type="s" number="2074" updated="2022-11-01T13:50:43Z">
  <state datetime="2019-07-10">REFERRED</state>
  <status>
    <introduced datetime="2019-07-10"/>
  </status>
  <introduced datetime="2019-07-10"/>
  <titles>
    <title type="display">Mainstreaming Addiction Treatment Act of 2019</title>
    <title type="short" as="introduced">Mainstreaming Addiction Treatment Act of 2019</title>
    <title type="official" as="introduced">A bill to amend section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to eliminate the separate registration requirement for dispensing narcotic drugs in schedule III, IV, or V, such as buprenorphine, for maintenance or detoxification treatment, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="H001076"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2019-09-23"/>
    <cosponsor bioguide_id="H001079" joined="2020-10-25"/>
    <cosponsor bioguide_id="M001176" joined="2019-10-16"/>
    <cosponsor bioguide_id="M001153" joined="2019-07-10"/>
    <cosponsor bioguide_id="S001198" joined="2019-07-29"/>
  </cosponsors>
  <actions>
    <action datetime="2019-07-10">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-07-10" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="2482" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Commerce"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Crime and Law Enforcement"/>
    <term name="Drug therapy"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Federal preemption"/>
    <term name="Government information and archives"/>
    <term name="Health care coverage and access"/>
    <term name="Health personnel"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2021-02-12T14:02:54Z" status="Introduced in Senate">Mainstreaming Addiction Treatment Act of 2019

This bill removes the requirement that a health care practitioner apply for a separate waiver through the Drug Enforcement Administration (DEA) to dispense certain narcotic drugs (e.g., buprenorphine) for maintenance or detoxification treatment (i.e., substance use disorder treatment).

Further, a community health aide or community health practitioner may dispense certain narcotic drugs for maintenance or detoxification treatment without registering with the DEA if the drug is prescribed by a health care practitioner through telemedicine. It preempts state laws related to licensure for this activity.

The bill also directs the Substance Abuse and Mental Health Services Administration to conduct a national campaign to educate health care practitioners and encourage them to integrate substance use disorder treatment into their practices.</summary>
</bill>
